FMP

FMP

Enter

ETNB - 89bio, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ETNB.png

89bio, Inc.

ETNB

NASDAQ

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

6.75 USD

0.17 (2.52%)

ETNB Financial Statements

Year

2023

2022

2021

2020

Total Revenue

0

0

0

0

Cost of Revenue

273k

240k

79k

60k

Gross Profit

-273k

-240k

-79k

-60k

Operating Expenses

151.2M

102.25M

89.74M

49.35M

Research and Development

122.23M

80.8M

70.33M

36.2M

Selling, General & Administrative Expenses

28.97M

21.45M

19.41M

13.16M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

28.97M

21.45M

19.41M

13.16M

Other Expenses

0

242k

-526k

-203k

Operating Income

-151.2M

102.25M

-89.74M

-49.35M

Total Other Income/Expenses Net

12.88M

242k

-526k

-203k

Income Before Tax

-138.32M

-102.01M

-90.27M

-49.56M

Income Tax

3.87M

19k

-147k

-59k

Net Income

-142.19M

-102.03M

-90.12M

-49.5M

Basic EPS

-2

-2.93

-4.48

-3.08

EPS Diluted

-2

-2.93

-4.48

-3.08

Basic Average Shares

71.17M

34.81M

20.1M

16.09M

Diluted Average Shares

71.17M

34.81M

20.1M

16.09M

EBITDA

-134.46M

-99.84M

-90.19M

-49.5M

Retained Earning Schedule

Year

2023

2022

2021

2020

Retained Earnings (Previous Year)

-315.24M

-213.22M

-123.09M

-73.6M

Net Income

-142.19M

-102.03M

-90.12M

-49.5M

Stock Repurchases

268k

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-457.43M

-315.24M

-213.22M

-123.09M

Other Distributions

-141.92M

-102.03M

-90.12M

-49.5M

PPE Schedule

Year

2023

2022

2021

2020

Gross PPE

2.34M

455k

150k

166k

Annual Depreciation

273k

240k

79k

60k

Capital Expenditure

-4k

-7k

-63k

-126k

Net PPE

2.07M

222k

134k

232k

Intangible and Goodwill Schedule

Year

2023

2022

2021

2020

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep